JAVED RAHMAT, M.D.; RICHARD L. GELFAND, M.D.; MICHAEL C. GELFAND, M.D.; JAMES F. WINCHESTER, M.D.; GEORGE E. SCHREINER, M.D.; HYMAN J. ZIMMERMAN, M.D.
Captopril, the competitive inhibitor of angiotensin-converting enzyme, is of considerable benefit in difficult-to-manage forms of hypertension. Its use has been associated with various untoward effects, but hepatic injury has not been widely reported. We treated a patient with captopril-associated cholestatic jaundice; a review of cases reported to the drug manufacturer and a review of the literature showed 13 additional cases of hepatic injury associated with captopril. In 9 of these the jaundice was categorized as cholestatic, and in 4 of the remaining 5 as mixed cholestatic-hepatocellular. These findings show that jaundice may be an idiosyncratic side effect of captopril, and that captopril-associated jaundice characteristically has strongly cholestatic features.
RAHMAT J, GELFAND RL, GELFAND MC, WINCHESTER JF, SCHREINER GE, ZIMMERMAN HJ. Captopril-Associated Cholestatic Jaundice. Ann Intern Med. ;102:56–58. doi: 10.7326/0003-4819-102-1-56
Download citation file:
Published: Ann Intern Med. 1985;102(1):56-58.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use